A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2019
Price : $35 *
At a glance
- Drugs Rivogenlecleucel (Primary) ; Rimiducid
- Indications Graft-versus-host disease
- Focus Adverse reactions
- Acronyms DOTTI
- Sponsors Bellicum Pharmaceuticals
- 25 Jan 2019 Planned End Date changed from 1 Dec 2019 to 1 Jul 2030.
- 25 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 14 May 2015 Data published in a Bellicum Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History